logo
School lunches, the French way: It's not just about nutrition, but togetherness and 'bon appetit'

School lunches, the French way: It's not just about nutrition, but togetherness and 'bon appetit'

Canada News.Net3 days ago
This spring, as part of a sabbatical project, I had the privilege of visiting school food programs and meeting with school food researchers in six cities in France, England and Scotland.
I got to eat school lunches, visit central kitchens in two cities where meals are prepared for thousands of children, visit school kitchens and discuss school food with the countries' leading experts.
This visit intersects with my research with colleagues on promising food programs across Canada. This research offers insights for consideration as regions navigate the federal government's first National School Food Program and National School Food Policy.
Government announcements about the program and policy were followed by negotiations with the provinces and territories, all of which have since signed agreements for a portion of the funding.
In most parts of Canada, officials are just beginning to plan for new approaches to school food (with a few exceptions especially in Atlantic Canada where school food programs have been transforming much more quickly).
Based on my research about international food programs, here are four key things Canadians should pay attention to:
1) In Canada we need to shift from thinking of school lunches as a safety net for kids living in poverty to thinking about them as benefiting the health and well-being of children and their families. In France, this shift in thinking is particularly clear.
School lunches in France are about teaching children about food and culture and all kids are encouraged to eat together with an adult facilitator who teaches them about the components of the meal and creates a family-meal context at each table. By contrast, if you ask many parents in Canada what school meals are for, they will tell you they are for kids living in poverty to make sure they have food to eat at school.
If Canada wants a national school food program that achieves the benefits of the best programs in the world in the areas of education, well-being and on the economy, we need to think of school meals as supporting young people to be the best students they can be.
2) One important benefit of school food programs globally is to encourage picky eaters to try new foods due to the social pressure of all kids eating the same foods together. In three cities in France I visited, and one in England, school lunches look like home-cooked meals. One main dish with meat is served (and in England, a vegetarian alternative), and kids can choose if and how much of the side vegetables and fruit to take.
In Canada, following a similar practice - one main and a vegetarian alternative when meat is served - might work well. But it's also important that in developing a menu, the cultural diversity of Canadian school communities is reflected in the food on offer.
In the other two locations in England and Scotland, kids choose from multiple main dishes - something that adds cost to the program and does less to encourage kids to try new foods, given one choice is always something basic like a cheese sandwich.
Kids need to have some autonomy when it comes to eating, but school food programs should not be facilitating eating the same food every day. Nor should school food programs aspire to a model where broad choice is afforded from a large menu.
3) With care, planning and sufficient resources, centralized kitchens can prepare thousands of servings of a main dish daily. The French central kitchens I visited prepare 6,000 to 10,000 servings a day of high-quality food following strict food safety protocols.
I ate two simple yet delicious meals cooked in municipally owned central kitchens. In the three cities in France where I visited, they used central kitchens where main dishes were prepared and chilled to be delivered for heating at the school level. Central kitchens also delivered the salads and sides (like chopped veggies, bread, cheese and fruit) and dressings.
In the small school kitchens, the salads were dressed, and the cheese and fruit were cut for service.
The central kitchens were also used in at least one city to prepare food for daycares and for seniors who were home-bound - something to consider for Canadian cities.
Centralizing kitchens can reduce costs and provide a way for high-quality food to be produced from basic ingredients without commercial kitchens in every school capable of preparing meals for hundreds of children at a time.
4) When designed with requirements for purchasing foods from local farmers and other Canadian producers, school food programs can benefit the agricultural sector and multiply their benefits to communities beyond direct school food jobs. In France, for example, there are specific percentages to be purchased from local and sustainable sources. Percentage requirements for local and sustainable purchasing should be enacted now in Canada as its program establishes itself, perhaps beginning with 20 per cent and growing over time.
I have many more reflections from my visits, both positive and negative, but the four I have discussed are important for Canada to learn from as it begins to design the National School Food Program to meet the needs of diverse communities from coast to coast to coast.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

GreenShield Expands Women's and Men's Health Offerings with Canada's First Personalized Hormonal Health Program Français
GreenShield Expands Women's and Men's Health Offerings with Canada's First Personalized Hormonal Health Program Français

Cision Canada

time3 hours ago

  • Cision Canada

GreenShield Expands Women's and Men's Health Offerings with Canada's First Personalized Hormonal Health Program Français

A bold step forward in health equity and innovation to support whole person wellness, GreenShield's new nurse-led program addresses a critical gap in hormonal health care—empowering Canadians across life stages. TORONTO, July 17, 2025 /CNW/ - Three in four Canadian women experience disruptive menopausal symptoms and one in four men face hormonal shifts like low testosterone. Despite this widespread impact, Canadians still face fragmented education and a one-size-fits-all approach to hormonal health care, which can often lead to worsened health outcomes and increased absenteeism in the workplace. GreenShield, Canada's only national non-profit health and benefits company, today announced the launch of its new Personalized Hormonal Health Program —a first-of-its-kind initiative designed to support Canadians through life-stage hormonal changes. Building on the integrated capabilities of GreenShield+—Canada's first fully integrated platform combining healthcare services and benefits coverage—GreenShield's comprehensive nurse-led Hormonal Health program merges clinical insights with personalized support to proactively manage hormonal health. Whether it's navigating the effects of perimenopause and menopause, or addressing andropause and low testosterone, the program is designed to empower all Canadians to take control of their hormonal wellness with care that adapts to their needs over time. "Hormonal health is not a niche issue—it's a national health gap," said Joe Blomeley, EVP, GreenShield Health. "Nearly half of Canadian women feel unprepared for menopause, and awareness of hormonal changes in men remains limited. Canadians deserve access to care that not only informs but empowers them to thrive through every stage of life. Our new nurse-led program is designed to support all individuals with personalized care that meets their evolving health needs. By delivering integrated, whole-person care, we're advancing our mission of Better Health for All and ensuring no one feels alone on their health journey." Designed to help members understand and manage the impact of hormonal changes on their everyday health—from energy and mood to sleep and metabolism—GreenShield's program includes: A complimentary nurse intake and assessment so employees can get a full picture of their health Full hormone panel testing A personalized care plan tailored to each member's needs Virtual consultations with a hormonal health provider (e.g., nurse practitioner) Ongoing health support via direct messaging Home delivery of any required treatments The program is fully connected into GreenShield's broader ecosystem—making it easy for members to access mental health services, telemedicine, pharmacy care, well-being tools, and their benefits plan all in one place. This creates a fully integrated, holistic care journey that supports members at every stage of their health experience. Whether the member knows exactly what they are looking for, or is unsure where to begin, GreenShield+ offers a guided, intuitive experience. Key features include: Life stage-based support: Tailored content and services that evolve with the member, addressing everything from reproductive health and parenting to menopause and healthy aging. Personalized, data-driven recommendations:"Next Best Action" suggestions that connect members to the right support at the right time. An intuitive interface: Simplified coverage and care navigation, helping members make more confident health decisions. "Hormonal changes can deeply affect a person's physical, mental, and emotional well-being—often leading to lower engagement and more time away from work," said Nadim Kara, Executive Vice President of People and Culture at GreenShield. "Our integrated model is designed to meet people where they are, making it easier to access holistic care that reflects their individual needs. This program is a clear example of how we're evolving our payer-provider model to support the real, everyday health needs of those we serve—including our own employees through our Total Rewards Program." GreenShield's Total Rewards program is market-leading across three priority areas that are core to the company's values: mental health, social impact and inclusion. Notably, the program includes $10,000 of mental health coverage per year, and donation matching of $3,000 per year towards charities of each employee's choice. Last month, GreenShield's Total Rewards Program expanded to include access to its new Hormonal Health program, including three consultations with a nurse practitioner. This offering builds on GreenShield's inclusive benefits for family building, gender affirmation and more, along with expanded plan choices that employees can customize to their lifestyle, all accessible through the GreenShield+ integrated health and benefits platform. About GreenShield As Canada's only national non-profit health and benefits company, GreenShield believes health care is a right, not a privilege. We're dedicated to improving health outcomes, driving systemic change, and building a future where every Canadian can reach their full health and well-being potential. We are revolutionizing the health and benefits experience with coverage and care in one place. Through our unique integrated payer-provider ("payvider") model, we offer insurance, administer benefits and pay claims as a 'payer' while offering health services such as mental health, pharmacy, telemedicine and chronic disease management as a 'provider'. As a non-profit social enterprise without shareholders, we prioritize and reinvest our excess earnings to directly support underserved communities. Through GreenShield Cares, we've committed $75 million to improve the health of over one million Canadians by the end of 2025, focusing on mental health, essential medicines, and chronic disease management. Our scalable initiatives deliver meaningful change in pursuit of Better Health for All. GreenShield is proud to be recognized as one of Canada's Most Admired Corporate Cultures, a leading Imagine Canada Caring Company, and named on the Fortune's Change the World List.

B.C. NDP admits Charleigh Pollock is the only kid in Canada to be denied funding for rare disease
B.C. NDP admits Charleigh Pollock is the only kid in Canada to be denied funding for rare disease

Vancouver Sun

time13 hours ago

  • Vancouver Sun

B.C. NDP admits Charleigh Pollock is the only kid in Canada to be denied funding for rare disease

VICTORIA — The B.C. New Democrats have made Charleigh Pollock the lone Canadian to be denied public funding for the only drug treatment for Batten disease, the fatal disorder that is ravaging the 10-year-old Langford girl. Health Minister Josie Osborne admitted to reporters Wednesday that 'Charleigh is the only patient in Canada currently who has been assessed to meet the discontinuation criteria for this drug.' But she defended the cutoff of funding for the drug Brineura, saying the government was guided by an expert-driven process 'that is essential to providing fair treatment to all patients.' A daily roundup of Opinion pieces from the Sun and beyond. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Informed Opinion will soon be in your inbox. Please try again Interested in more newsletters? Browse here. Osborne's claim of fair treatment was as hollow as her insistence that she and her colleagues hold Charleigh and her family 'in our hearts.' The contradictory evidence is right next door in the province of Alberta. Meet Madden Stacey, a boy just one day younger than Charleigh, and the only child in Alberta with Batten disease. Madden's treatment with Brineura is still fully funded by the province of Alberta, according to his father Aaron, a resident of Fort McMurray. 'Not only has it extended an already very short life span. We get to spend more time with him. Without it, we would have been in a lot of trouble,' Aaron told Mary Griffin of CHEK News. 'This disease is devastating. It comes with a lot of seizure activity — the ability to walk, sleep, eat, it's all affected by the disease. And Brineura has brought some comfort to our lives and Madden's in the last five years that he's been taking the infusions.' Charleigh's mother, Jori Fales, has described the ravages of Batten disease in similar terms. Multiple seizures every day. The child turning blue and choking. But those symptoms have retreated with the application of Brineura. Charleigh has been able to go to school, and celebrate her 10th birthday with friends. Happily, restoration of the drug should be starting today. Charleigh is scheduled for a renewed treatment with the drug, thanks to money raised on GoFundMe. The Island Health region helped secure access to the drug and will oversee its administration. Osborne was asked to explain the government's willingness to administer the drug while at the same time discounting its efficacy. The decision to go with private funding was taken by the family, backed by the doctor who has been treating Charleigh, the minister replied. 'They're moving forward, and Island Health is enabling the use of their facilities to be able to do that. The decisions to continue applying the treatment will rest with the physician and her care team. 'We're here to support them in every way that we can, while we continue to follow the evidence-based processes that we have (for) establishing the reimbursement criteria for the public funding of drugs.' Translation: We think the drug is useless but we'll deliver it, so long as you pay cash up front. The glaring contradiction drew scorn from Port Coquitlam Mayor Brad West, a longtime New Democrat and former staffer to, and campaign organizer for, cabinet minister Mike Farnworth. 'When I first got involved in politics and joined the NDP, it was in the 2000s because of some of the cruelty I felt over some of the decisions of the (Gordon) Campbell government,' West told Mike Smyth on his CKNW show Tuesday. 'When I was involved in the NDP, you could barely go to a party gathering without them referencing the fact that they're the party of Tommy Douglas. And now they're the party of GoFundMe health care.' From Tommy Douglas health care to GoFundMe health care. Don't be surprised if that line makes it into the next round of attack ads from the Opposition. 'To me, this is about a little girl. But this is also saying something about who we are as a people and what we value and what's important,' said West. 'Again, I'm struggling on a personal level. I'm struggling as someone who has been involved and supported this party, that they would just stand by with a cold, cruel indifference and just say, 'Well, this is the system, this is the way it works.'' I've heard a lot of comments along those lines, including from people who identify themselves as NDP supporters. I gather NDP MLAs and ministers are hearing it in their constituency offices and emails too. One who should be feeling the heat is Ravi Parmar, the minister of forests and MLA for Langford-Highlands, the riding where Charleigh lives. He is regarded as a rising star in the NDP. On this issue, his only public statement has been a perfunctory justification for the bureaucratic cutoff of funding for the little girl, followed by the nonsensical claim that the NDP will therefore 'continue to push for a health care system that puts people first, because that's what families deserve.' Parmar's predecessor as NDP MLA for Langford was a fellow named John Horgan. Imagine Horgan's reaction when confronted with such a parade of bureaucratic guff. Charleigh would still be getting her treatment today, but with the difference that it would be paid for by the provincial government. vpalmer@

Cheaper generic Ozempic is coming to Canada after Novo Nordisk fails to pay patent fee
Cheaper generic Ozempic is coming to Canada after Novo Nordisk fails to pay patent fee

The Province

time17 hours ago

  • The Province

Cheaper generic Ozempic is coming to Canada after Novo Nordisk fails to pay patent fee

Novo Nordisk reportedly failed to pay its annual fees to maintain the patent rights in Canada, opening the door to cheaper generic copycats Several applications for generic semaglutide, the active compound in Novo Nordisk's injectable drugs Ozempic and Wegovy, are now before Health Canada. Getty Images In what Science magazine has dubbed 'Novo Nordisk's Canadian Mistake,' Ozempic is soon to come off patent in Canada, opening the door to cheaper generic copycats, after the drug giant reportedly failed to pay a few hundred dollars in annual fees to maintain the patent rights before the weight-loss drug became a blockbuster seller. This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Exclusive articles by top sports columnists Patrick Johnston, Ben Kuzma, J.J. Abrams and others. Plus, Canucks Report, Sports and Headline News newsletters and events. Unlimited online access to The Province and 15 news sites with one account. The Province ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles and comics, including the New York Times Crossword. Support local journalism. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Exclusive articles by top sports columnists Patrick Johnston, Ben Kuzma, J.J. Abrams and others. Plus, Canucks Report, Sports and Headline News newsletters and events. Unlimited online access to The Province and 15 news sites with one account. The Province ePaper, an electronic replica of the print edition to view on any device, share and comment on. Daily puzzles and comics, including the New York Times Crossword. Support local journalism. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors As Science reported, a patent, once lapsed, can't be restored. Novo Nordisk will continue to hold its U.S. patent until 2032. Ozempic was already the third most prescribed drug in Canada last year with 7,390,000 prescriptions dispensed, a 17 per cent increase over 2023, according to drug analytics research firm IQVIA. Several applications for generic semaglutide, the active compound in Novo Nordisk's injectable drugs Ozempic and Wegovy, are now before Health Canada. Last week, a U.S. telehealth service announced plans to expand into Canada next year and offer generic semaglutide at a significant discount. Richard Saynor, the head of Sandoz, a global leader in generic and biosimilar drugs, told Endpoint News in June that his company has filed for approval for a generic semaglutide in Canada once Novo Nordisk's patent exclusivity expires 'sometime in Q1 next year.' This advertisement has not loaded yet, but your article continues below. Canada is the globe's second-biggest semaglutide market, Saynor told Endpoint News. 'You gotta ask why. I don't think Canadians are disproportionately large. There's clearly a dynamic, like insulin, with cross-border business,' he said. Americans with diabetes have crossed into Canada to buy insulin at much lower prices. Ozempic and Wegovy cost about $5,000 per year. If money is no longer a factor, if chemically-identical drugs are cheaper and more affordable, 'that's going to change the calculus for many people,' said Justin Lehmiller, a senior research fellow at Indiana University's Kinsey Institute and co-author of a new survey exploring the impact that weight-loss drugs — formally known as GLP-1 agonists — are having on dating and intimacy. Essential reading for hockey fans who eat, sleep, Canucks, repeat. By signing up you consent to receive the above newsletter from Postmedia Network Inc. Please try again This advertisement has not loaded yet, but your article continues below. The survey of 2,000 single Americans (aged 18 to 91) led by Kinsey with found eight per cent reported having used a GLP-1 medication for weight loss in the past year. Among the GLP-1 users, 16 per cent said exes had reached out to reconnect, 14 per cent said they were getting more matches on dating apps and 12 per cent said they were going on more dates. The drugs seemed to be doing more to booster 'online dating success' for men than for women, the researchers said. 'Some of the studies and research that I've seen suggest that men only match one in 100 times on dating apps where for women, it's more like one in 10,' Lehmiller said. 'An attractiveness boost for men, which often accompanies using these drugs, could translate into a much bigger impact for them in the world of dating.' This advertisement has not loaded yet, but your article continues below. Men, however, were nearly twice as likely to women to say they feared being judged or shamed for taking Ozempic or other GLP-1 drugs. 'There are some masculinity concerns that are tied up in this,' said Lehmiller, a social psychologist. Men might worry about being accused of cheating, he said. 'It might be viewed as a sign of weakness for turning to a drug as opposed to losing weight through 'hard work.'' About half of the GLP-1 users also said the medications impact their sex lives, in both positive and negative ways: 18 per cent said their sexual desire increased, while 16 per cent said it dropped. Sixteen per cent said their sexual function improved; 12 per cent said it worsened. It's a nuanced picture, Lehmiller said. 'These drugs seem to be affecting different people in different ways.' This advertisement has not loaded yet, but your article continues below. 'And I think that makes sense: There is a lot of variability in the side effects people experience on these drugs.' More side effects might mean more negative impact on intimacy, he said. The drugs have also been associated with a slightly higher risk of erectile dysfunction and testosterone deficiency in men taking semaglutide for obesity compared to men not taking the drug. About one in five in the dating survey said the drugs are creating more stigma against being overweight. 'Changing standards of attractiveness might be creating more pressure for people to look a certain way or use these medications,' Lehmiller said. A study published this week in the Canadian Medical Association Journal found 32.7 per cent of adults in Canada (10.6 million people) were obese in 2023, an eight per cent jump over 2009. This advertisement has not loaded yet, but your article continues below. Generic semaglutide won't be as cheap as Aspirin. 'It's still going to be a cost,' said Dr. Hertzel Gerstein, an endocrinologist and professor in McMaster University's department of medicine. 'And that does not relieve a responsible health practitioner of assessing a patient before they prescribe the medication,' he said. 'Is it possible that more people would be willing to pay out of pocket if they don't have insurance coverage for the drug? Sure, if it's cheaper,' Gerstein said. 'There may be more demand for it. People need to understand the risks and benefits.' Taken once a week by injection, Ozempic and Wegovy work by mimicking a hormone — glucagon-like peptide-1 — the small intestine releases when people eat. GLP-1 tricks the body into thinking it's full. It works on the brain to reduce appetite and interest in continuing to eat, and works on the stomach to slow how fast it empties so that food lingers in the stomach longer. This advertisement has not loaded yet, but your article continues below. Semaglutide has been studied extensively, Gerstein said. The amount of weight lost is related to the dosage: the higher the dose, the more weight dropped. In people with type 2 diabetes, the drug can reduce the need for insulin, or the dosage. 'But most importantly these drugs unequivocally reduce the future risk of serious health outcomes, including heart attacks, strokes, death from cardiovascular causes' and heart failure symptoms when used long-term, 'in the two- to five-year window of time,' Gerstein said. A major analysis published earlier this year based on health data from more than two million Americans veterans with diabetes found that, compared to more traditional drugs, GLP-1 use was associated with a reduced risk of substance use (alcohol, cannabis, stimulants and opioids), psychotic disorders such as schizophrenia, seizures, several respiratory conditions and neurocognitive diseases like Alzheimer's and dementia. This advertisement has not loaded yet, but your article continues below. The magnitude of the associated benefits — about a 10 to 20 per cent reduction for most outcomes — was modest, according to a background release, though the researchers said they don't 'negate' the potential value of the drugs. There were, however, several drawbacks, including an increased risk of gastrointestinal disorders (nausea, vomiting, diarrhea), low blood pressure, fainting, arthritic disorders, kidney disorders and drug-induced pancreatitis associated with GLP-1 drugs compared to usual care. Nothing is guaranteed, Gerstein said. 'I always tell patients we don't know exactly what it'll do in you. And weight loss, if it's going to happen, usually takes a month or two to start' and plateaus at around eight months. People don't lose weight indefinitely. 'There's definitely a plateau. You do not keep losing weight,' he said. The drugs yield an average weight loss of around 15 per cent, and weight can also rebound rapidly once the drugs are stopped. This advertisement has not loaded yet, but your article continues below. Ozempic has been approved in Canada for diabetes but is often used 'off label' for obesity. Wegovy has been approved for obesity. In an email to National Post, Novo Nordisk, the only current company in Canada with Health Canada-approved products containing semaglutide, said 'all intellectual property decisions are carefully considered at a global level. 'Periods of exclusivity for pharmaceutical products end as part of their normal lifecycle and generic treatments may become available over time,' the company said. 'Currently, no Health Canada-approved generic versions of semaglutide exist and we cannot speculate on other manufacturers' plans,' it added. National Post Read More Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our newsletters here. Crime News News News News

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store